1 October 2018 - Biofrontera announced today that Swissmedic, the Swiss national approval and supervisory authority for drugs and medical products, has approved the extension of the label of Ameluz to its use in combination with photodynamic daylight therapy.

The Swiss approval of Ameluz with daylight-PDT follows the EU approval by the European Commission in March 2018. Ameluz is marketed in Switzerland by Louis Widmer, which also functions as local marketing authorisation holder. The approval of the label extension is now followed by the submission of documents for reimbursement in order to include Ameluz in combination with daylight-PDT in the Swiss Federal Office of Public Health's list of specialties. 

This would provide patients in Switzerland with an almost painless treatment option that offers high efficacy and excellent cosmetic results as an insurance benefit. Biofrontera and Louis Widmer expect a sales effect for the summer months of 2019 comparable to the one experienced in the German market this year.

Read Biofrontera press release